key: cord-1041225-jhub5es6
authors: Pranata, Raymond; Henrina, Joshua; Raffaello, Wilson Matthew; Lawrensia, Sherly; Huang, Ian
title: Diabetes and COVID-19: The Past, The Present, and The Future()
date: 2021-06-11
journal: Metabolism
DOI: 10.1016/j.metabol.2021.154814
sha: f0bb880dbcae8bd637a6ca02f28be34fe3c82bed
doc_id: 1041225
cord_uid: jhub5es6

Diabetes, one of the most prevalent chronic diseases in the world, is strongly associated with a poor prognosis in COVID-19. Scrupulous blood sugar management is crucial, since the worse outcomes are closely associated with higher blood sugar levels in COVID-19 infection. Although recent observational studies showed that insulin was associated with mortality, it should not deter insulin use in hospitalized patients requiring tight glucose control. Back and forth dilemma in the past with regards to continue/discontinue certain medications used in diabetes have been mostly resolved. The initial fears of consequences related to continuing certain medications have been largely dispelled. COVID-19 also necessitates the transformation in diabetes care through the integration of technologies. Recent advances in health-related technologies, notably telemedicine and remote continuous glucose monitoring, have become essential in the management of diabetes during the pandemic. Today, these technologies have changed the landscape of medicine and become more important than ever. Being a high-risk population, patients with type 1 or type 2 diabetes, should be prioritized for vaccination. In the future, as the pandemic fades, the prevalence of non-communicable diseases is expected to rise due to lifestyle changes and medical issues/dilemma encountered during the pandemic.

More than a year has passed since the emergence of coronavirus disease of 2019 caused by the respiratory virus, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) from Wuhan, China. Numerous risk factors for severe COVID-19 and poor outcome have been glucose level and glycolysis mediate mitochondrial reactive oxygen species production and activate hypoxia-inducible factor 1α, which increases viral replication. [15, 16] Lastly, there might be direct implications between glucose impairment and cytotoxic lymphocytes natural killer (NK) cell activity. A multiple regression analysis shows that the HbA1c level serves as an independent risk factor for NK cell activity. [17] Compared to patients without T2DM, lower NK cell activity is found in patients with pre-existing Type 2 diabetes (T2DM) and prediabetes. [17] Nevertheless, to the best of the authors' knowledge, there is no solid real-world data that shows increased susceptibility to SARS-CoV-2 infection in patients with diabetes, despite the theoretical risk. [18] 

Since the early pandemic, diabetes has been identified as a risk factor for poor outcomes in the COVID-19 disease, such as progression to acute respiratory distress syndrome (ARDS) and mortality. Nonetheless, early data accrued from several observational studies, despite being timely, have poor quality in general because the emphasis on the rapidity, which sacrificed important epidemiologic fundamentals. Thus, it precludes a complete understanding of diabetes and other comorbidities and their impact on COVID-19. [19] Here we described metaanalyses and several important observational studies that greatly contribute to our understanding on DM and COVID-19.

In a meta-analysis of 6452 hospitalized COVID-19 patients involving 30 studies, those with DM were at twice the increased risk for mortality and disease severity. A major limitation of this meta-analysis was patient duplication and repeated analysis, which may show misleading results. [4] Another meta-analysis of the same topic but addressing this problem showed that the prevalence of DM in hospitalized COVID-19 patients was 12%. Moreover, DM was associated with a higher risk for intensive care unit (ICU) admission (relative risks (RR) of 1. 96 P< 0.001]), but not severe disease. [20] Nevertheless, this study cannot exclude the effect of confounders.

A whole-population study in England encompassing 61,414,470 individuals found that diabetes is found in one-third of non-survivors. In a multivariate analysis, compared to their non-diabetic counterparts, the odds ratios (ORs) for in-hospital mortality were 2.86 (95% CI 2.58, 3.18) type 1 diabetes mellitus (T1DM) and 1.80 (95% CI 1.75, 1.86) for T2DM. However, these findings are limited because residual confounders (smoking history, body mass index (BMI), incomplete cardiovascular comorbidities) not addressed by the model. [21] Several risk factors associated with mortality in England due to COVID-19 in T1DM and T2DM patients have been identified through a population-based cohort study by Holman et al. [22] Utilizing a national dataset of patients with diabetes registered in general practice, they found that, other than the well-known risk factors, this study identified glycemic control (HbA1C), and BMI as independent predictors of the primary outcome ,i.e. COVID-19 related death. Compared to patients with HbA1C of 48 -53 mmol/mol (6.5 -7.0%), those with HbA1C of ≥86mmol/ mol (10.0%), were at 113% and 61% increased risk of COVID-19 related death in patients with T1DM and T2DM, respectively. Additionally, they found that patients younger than 70 years old were at excess risk. Significantly, this study added the body of evidence of social determinants of health (SDoH), as evidenced by increased HRs for the most deprived population and minorities (Black, Asian, and minority ethnicities).

In another prospective cohort study, involving all Scottish populations, T1DM and T2DM people were at increased cumulative risks of fatal or critical-care treated COVID-19 vs. those without, even after age and sex adjustment, with their respective ORs of 2.40 (95% CI 1.82, 3.16; p<0·001) and 1.37 (95% CI 1.28, 1.47; p<0.001). [23] More importantly, this study showed that among people with diabetes, collectively those with more severe DM and in vulnerable populations (living in a residential care or deprived area), and smokers were more likely to develop outcomes, which remained significant after adjusting for age, sex, and diabetes type and duration.

Meanwhile, a nationwide retrospective cohort study from the UK evaluating COVID-19

Hospitalisation in England Surveillance System (CHESS) found that COVID-19 patients with T2DM hospitalized in the critical setting (high dependency unit (HDU) and ICU were at 23% increased risk all-cause mortality; adjusted hazard ratio (aHR) of 1.23 [95% CI 1.14, 1.32]), J o u r n a l P r e -p r o o f which was lower than the aforementioned studies. [24] Importantly, the aHR for the younger age group (age 18-49 years) were significantly higher compared to the older groups ( pre-admission variable that was associated with the primary outcome, i.e., composite of tracheal intubation and/or death within 7 days of admission. Second, several laboratory examinations at admission were associated with the primary outcome, namely lymphocyte count, c-reactive protein level (CRP), and aspartate aminotransferase (AST). Micro and macrovascular complications related to diabetes were associated with the risk of death on day 7 . Surprisingly, long-term glucose control (HbA1C levels) was not associated with the primary outcome. Nevertheless, substantial HbA1C levels that were missing remain a caveat before drawing a definite conclusion. The same investigators also established prognostic factors associated with discharge and death within 28 days, these include microvascular complications, dyspnea on admission, routine anticoagulant therapy, higher AST, CRP levels, and white cell count. Interestingly, statin and insulin therapy were associated with higher deaths within 28 days. [26] Additionally, these investigators also highlighted hospitalized COVID-19 patients with T1DM, with the prevalence of 2.1%, much lower than the general population, ie, 5.6%.

Furthermore, compared to their T2DM counterparts, these patients were at half of the risk of death on D7 (10.6% vs. 5.4%). Notably, the T1DM group was significantly younger than the T2DM group ((56.0 6 16.4 vs. 70.5 6 12.5 years), with those <55 years were three times less likely to achieve primary outcome of death/ intubation on D7 than the T2DM group. [27] In a prospective study, Gregory et al. found that T1DM triples the risk of COVID-19 related hospitalization and severity of illness that persists after adjustment for confounders. Their respective OR were 3.90 (95% CI 1. 75, 8.69 ) and 3.35 (95% CI 1. 53, 7.33) . Importantly, this study highlighted the probability of patients with T1DM to be hospitalized were at 15 -22%, J o u r n a l P r e -p r o o f which was substantially higher than those without (5%). Additionally, this study highlighted the impact of SDoH on the severity of outcome, primarily in the underserved populations.

Consistently, the role of SDoH was also seen in another multisite cross-sectional study involving 113 cases of T1D patients with COVID-19. [28] Moreover, long-term glucose control (HbA1C levels) was the only significant predictor for hospitalization, with higher HbA1C associated with 43% increased risk (OR 1.43 [95% CI 1.16, 1.82]). The finding of selected studies on diabetes and poor outcome in COVID-19 is summarized in Table 1 .

Patients with underlying chronic illnesses, which often co-exists in patients with diabetes, have an increased risk of developing severe COVID-19 with higher mortality and ICU admission. [5, 15, 22, [29] [30] [31] Reasons for poorer outcomes in COVID-19 patients with DM have been described in detail elsewhere. [32] Notably, we highlighted T2DM and obesity due to similar pathomechanisms between them. [33] Obesity frequently co-exists with diabetes and is unequivocally associated with poorer outcomes in COVID-19 infection. Several reasons may explain poor outcomes associated with obesity, as follows. First, obesity may worsen respiratory distress in COVID-19 by hampering the respiratory mechanics, reducing minute ventilation, and reducing functional reserve capacity. [34] Furthermore, obesity is associated with chronic low-grade inflammation. Visceral fat produces inflammatory cytokines (inflammokines) and ACE2 receptors on visceral fat is a possible site of viral replication, which consequently causes a higher viral burden in obese patients. [35, 36] Therefore, in the background of heightened inflammatory state, COVID-19 infection may trigger a cytokine storm. Also, obesity is associated with higher events of thromboembolic events. Compounded with COVID-19 infection, which is associated with a prothrombotic event, the thromboembolic risk may increase several-fold. [37, 38] Historically, obese patients were at lower risk of death due to pneumonia and ARDS. This phenomenon is known as the obesity paradox. [34, 39] Nevertheless, accumulating body of evidence refute this mortality benefit seen in obese patients. The NHS study from England found that the relationship between BMI and COVID-19 related death was a U-shaped curve. increased risk of achieving a primary outcome in hospitalized COVID-19 patients. [40] Interestingly, this observation only exists in patients <75 years old. Several studies indicate that visceral adiposity, but not subcutaneous adiposity, was significantly associated with poor outcome in patients with COVID-19 [41] [42] [43] , the apparent benefit or null-effect of obesity in some circumstances might be explained by variation related to visceral adiposity.

Bello-Chavola, et al. showed that almost half of the impact of diabetes on lethality (49.5%), was attributable to obesity. [44] Notably, diabetes that occurred in the Mexican is a distinct phenotype, ie, early-onset diabetes, which is associated with obesity, a rapidly declining β cell function, and a higher risk of microvascular complications.

A detailed description of diabetes management in COVID-19 patients and in general amid the pandemic is available on previous review articles. [45] [46] [47] [48] We underscored the three most pertinent aspects of diabetes management: i.e. health-related technologies, blood glucose controls, and antidiabetic agents and their mechanisms relating to immunomodulators.

Before the pandemic, there has been sparse adoption of health-related technologies in managing diabetes, with the pediatrics field leading the race. Now, the COVID-19 pandemic has transformed our healthcare systems dramatically and necessitated the early adoption of these technologies. [49] J o u r n a l P r e -p r o o f Overall, two health-related technologies played crucial parts amid the pandemic, i.e., telemedicine and remote continuous glucose monitoring (rCGM)

Platinum CGM System) in a patient with T2DM and covid-19 in a 68-years-old man. [50] Despite increased insulin needs for the patient (0.8 to 6.8 unit/hour), hypoglycemic events were prevented, with the glucose range of 100 -350 mg/dL. Also, rCGM led to decreased invasive procedures for blood glucose (BG) testing, consequently decreasing contact with healthcare workers (HCWs).

In a case-series, the combination of telehealth monitoring and CGM enabled patients with diabetic ketoacidosis to be managed as outpatients. Telemedicine has increased accessibility to providers for T1D patients. Meanwhile, telemedicine and patient's BG data provided by the CGM enabled providers to manage T1D optimally. This is reflected in the series, wherein one patient with a new-onset T1D, her BG levels were only 13% in time in range (TIR; 70 -180 mg/dL) on day one, and improved significantly on day 12 with TIR more than 90% and none in time below range (TBR; <70 mg/dL). [51] Another series by the same group highlighting the successful management of new-onset T1D through telemedicine with the help of CGM. [52] Two patients (20-year-old white male (patient 1) and 12 months white female (patient 2) with new-onset T1DM, who were initially treated in Barbara Davis Center for Diabetes, and subsequently discharged for telehealth monitoring. Patient 1 experienced improvement in TIR glucose levels from 16 to 37 to 91% with no TBR, while improvement between meals and overnight glycemic profiles over the course of 2 weeks was seen in patient two.

Moreover, another series showed that rCGM initiation through telehealth in 34 DM patients (27 T1D, 7 T2DM on insulin) was sustainable, with usage rate nearing 95% and CGM was used at least 6 days/ week. [53] More importantly, glycemic control improved substantially, with Mean HbA1c at 12 weeks of 7.2 +/-1.3 (baseline: 8.3 +/-1.6) and mean TIR of 59% +/-20% (baseline: 48% +/-18%), which translated to increase of TIR approximately 2.7 hours/day. Finally, two series underscored the usefulness of rCGM in the ICU settings. The first study by Agarwal, et al. involving 11 critically ill patients due to COVID-19 showed that validated real-J o u r n a l P r e -p r o o f time continuous glucose monitoring (rtCGM) is a potential addition to the standard point of care (POC) glucose testing as it is feasible, acceptable, and reliable. [54] Moreover, through this technology, a 60% reduction of potential POC tests from 60 to 28, with the majority (77.7% values, n= 493) of rtCGM-POC paired values fell within 20% of those in POCs, as recommended by the FDA.

Consistently, the benefit of rCGM was evidenced in the following study. A case series involving 5 ICU patients and one ambulatory patient to identify the usefulness of a new platform designed for simultaneous monitoring demonstrated improvement in TIR in all patients and prevented hypoglycemia. [55] Notably, no adverse events reported in the monitored ambulatory patients (199 days of remote monitoring)

In summary, these two technologies are beneficial for remote management of DM and will be practice-changing in the future. Of note, however, regulatory and policy reforms for telemedicine and the provision of CGM for the underserved populations are needed if widespread adoption is meant to be reached. The finding of selected studies on diabetes technology is summarized in Table 2 .

An accumulating body of evidence showed that glycemic control is crucial for hospitalized . Progression to critical cases/death in non-critical cases and in-hospital mortality in critical cases were also seen among patients with higher BG levels during the hospital stay or after critical diagnosis. Consistently, this was also the case for patients without DM but with elevated BG levels. [57] Contrarily, when evaluating the degrees of hyperglycemia impact on all-cause mortality, hyperglycemia (fasting glucose 5.6-6.9 mmol/L and/or HbA1c 5.7-6.4%) did not increase the all-cause mortality after multiple adjustments, despite higher ICU admission and invasive mechanical ventilation (6.2% vs. Zhu, et al. stressed the importance of good glycemic control in patients with pre-existing DM. In their retrospective longitudinal multi-centered study involving 7339 confirmed COVID-19 cases examining the impact of diabetes status and glycemic control in patients with pre-existing type 2 diabetes mellitus on mortality rate, the authors found that T2DM significantly increased the risk of COVID-19 related death. [59] Moreover, for those with pre-existing T2DM with poor glycemic control (BG >10 mmol) compared to well-controlled BG (3.9 -10 mmol), the previous group experienced higher all-cause mortality and COVID-19 related complications. The findings were still significant, even after propensity score matching, to minimize the effect of the confounder.

Fasting blood glucose (FBG) on admission also appears to be useful as a prognostic tool. The Correspondingly, the adjusted odds ratios (aOR) for the remainder quintiles were 25 Furthermore, hyperglycemia on admission (>7.77 mmol/L) exhibited higher interleukin-6 (IL-6) and D-Dimer levels, and clinically translated with more patients in this group achieved a composite of poor outcomes. Notably, insulin usage improved glycemic control, which consequently improved patients' outcomes. [62] Another study relating to at-admission hyperglycemia (≥7.78 mmol/L) showed that hyperglycemia, but not DM, was a consistent predictor for mortality even after adjustment for age and male gender, clinical confounders, as well as biomarkers. Furthermore, based on quintile grouping, patients with BG at Q4 and Q3 had a higher mortality rate than Q1. A threshold effect was seen in Q5, where no prognosis worsening occurred. [63] Another Important feature of FBG on COVID-19 severity is nonlinearity, i.e., the magnitude of FBG increment and its impact on COVID-19 severity differs in different baselines. Barrack, et al.

showed that an increment from 5 to 10 mmol/L is associated with a substantial increase in the Table 3 .

Careful selection of glucose-lowering medication in COVID-19 infection is crucial as several glucose-lowering agents might impact the immune system in combating the infection. Patients' clinical status and organ function have to be considered as several glucose-lowering medications might not be suitable for severe sepsis or severe impairment of hepatic and renal function. [65] Metformin is one of the most utilized glucose-lowering agents, exerts anti-J o u r n a l P r e -p r o o f inflammatory actions, and reduces circulating inflammatory biomarkers in patients with T2DM. [66, 67] However, there is scarce information about the effect and interactions of metformin in coronavirus infections. This uncertainty leads to no warrant for the use of metformin, especially in patient with severe hepatic and renal impairment. [65] Dipeptidyl peptidase (DPP4) inhibitor is a commonly used glucose-lowering agent in patient with T2DM. [65] DPP4 is a widely expressed cell surface endopeptidase that interacts with cellular proteins and generates intracellular signaling for the immune system. [68] DPP4 also regulates the expression of several chemokines and serves as a marker of activated T lymphocytes. [69] [70] [71] Both ACE2 and DPP4 is shed from the cell membrane and may circulate while retaining its catalytic actions. [72] The possibility of increased viral infection due to the inhibition of DPP4 raised has raised some concerns. Fortunately, DPP4 inhibitors seem not to alter the circulating leukocyte. One study showed no significant differences in leukocytes percentage and plasma chemokine/cytokine levels after 28 days of sitagliptin administration compared to the control group. [73] In another study, evidence has shown no direct association between the use of DPP4 inhibitors and increased risk of community-acquired pneumonia in DM patients. [74, 75] Another interesting finding is the possibility of SARS-CoV2 might bind to either DPP4 surface receptor or soluble DPP4, even though the role of soluble DPP4 in viral clearance is in doubt. [76, 77] Up until date, the use of DPP4 inhibitor is not associated with worse outcome, and the possibility of alteration in the viral receptors, the T cell functions or even the improvement of clinical outcomes in patients with COVID-19 remain inconclusive, and further studies are needed. [15, 25, 65, [78] [79] [80] [81] The use of glucagon-like peptide 1 (GLP1) analogue is well known for reducing major cardiovascular complications in T2DM patients. [82] Aside from the glucose lowering effect, GLP1 is well known to reduce the accumulation of the monocyte to various tissues and regulate the inflammation in macrophage, therefore helping in reducing the process of atherosclerosis. [83] One study demonstrates the IL-6 lowering effect of GLP1 infusion in patients with T1DM. [84] Presevering the cardiovascular and renal function are both essential J o u r n a l P r e -p r o o f and challenging during COVID-19, as both pre-existing chronic conditions are prevalent in patients with DM. While the use of glucagon-like peptide 1 (GLP1) analogue is well known in reducing major cardiovascular complications in T2DM patients in combination with potential mechanism of GLP1 in reducing various inflammatory cytokines sheds light on diabetes management during COVID-19 infection. [82, 85] Sodium-glucose cotransporter 2 (SGLT2) inhibitors are commonly used in treating T2DM, mainly acting on the kidney SGLT2 to reduce blood sugar levels. SGLT2 inhibitors are known to reduce inflammatory cells infiltration into arterial plaque and modulate the mRNA expression of certain cytokines such as IL-6 and tumor necrosis factor (TNF). [86, 87] The cardioprotective effect in the context of heart failure is one major advantage with the use of SGLT2. [65] However, the use of SGLT2 inhibitors in critical patients is not without risks.

Administration of SGLT2 inhibitors might be limited in critically ill patients as the fluid status of the patients have to be monitored closely. The use of SGLT2 inhibitors might cause osmotic diuresis that may lead to dehydration and hemodynamics alteration. [65, 88] Another limitation in using SGLT2 inhibitors is the patient's glomerular filtration rate which is typically reduced during the critical period, and therefore the glucose-lowering effects will be limited in these patients. Euglycemic ketoacidosis might also develop as a consequence of the use of SGLT2 inhibitors. [88] Another potential glucose-lowering agent in modulating inflammatory and oxidative stress has been proposed. Thiazolidinedione exerts its glucose-lowering effect by acting on the nuclear receptor that regulates glucose and lipid metabolism. [89, 90] It is proposed that the effect of thiazolidinedione on lowering insulin resistance in the liver and muscle is mainly mediated by modulating the endocrine signaling pathway in adipose tissue. [89] However, weight gain and edema are potential side effects of thiazolidinedione which is unfavorable in patients with a history of heart failure. [91] To date, the use of thiazolidinedione in patients with COVID-19 is still limited and needs further research.

The role of insulin for hospitalized COVID-19 patients with DM or hyperglycemia is controversial. [62, 92, 93] In one study, T2DM patients with COVID-19 who received insulin were at increased risk of death, even after propensity matching analysis (aHR of 5.38 and 3.21, J o u r n a l P r e -p r o o f respectively). [92] Nevertheless, residual confounders could not be ruled out, and those who received insulin were generally sicker and has higher glucose levels that requires insulin use in the first place. Additionally, it is unlikely that this hypothesis will be tested in future randomized controlled trials due to ethical problems. [18] Taken in sum, of all agents that are mentioned above, prudent selection of glucose-lowering agents is salient. As a consequence of the precipitating infection, acute hyperglycemia should be anticipated, and rapid blood sugar control should be achieved. Vague evidence regarding insulin should not deter its use in hospitalized patients requiring tight glucose control. The finding of selected studies on antidiabetic drugs is summarized in Table 4 .

Pancreatic involvement in patients with COVID-19 is possible because pancreatic injury was reported in hospitalized patients in China. Pancreatic injury was defined as increased amylase and lipase. Among 52 patients, 9/52 and 6/52 were found with pancreatic injury and elevated glucose levels, respectively. [94] Whether the acute hyperglycemia was due to pancreatic injury alone or as a part of complex interplay between other possible mechanisms is inconclusive.

Attention is now directed towards an increased frequency and severity of acute life-threatening complications of diabetes in hospitalized patients, which is suspected due to COVID-19 potential diabetogenic effect. [95] A cohort study conducted in the United States of America, which includes 5029 patients with diabetic ketoacidosis (DKA), has several notable findings in the differences of clinical characteristics between patients with COVID-19 and without COVID-19 that might bring some critical clues. From the perspective of age, patients with COVID-19 tend to be older than patients without COVID-19 (56 ± 17 years vs. 47 ± 18 years; p= < 0.001). [96] Another finding in patients with COVID-19 has a higher body mass index in comparison to patients without COVID-19 (31 ± 9 kg/m 2 vs 28 ±8 kg/m 2 ; p= <0.001). [96] Mortality and daily insulin dose are also higher in the patients with COVID-19 than patients without COVID-19. (with diabetes), HR 0.43, p= 0.038 (without diabetes)). [103] There was a lack of study that J o u r n a l P r e -p r o o f addresses the mechanistic basis that may alter immunological response in patients with diabetes receiving vaccination. In sum, the immunological response of patients with DM will likely be comparable to non-DM patients.

Another issue is regarding vaccine rollout prioritization. Initially, the Centers for Disease Control and Prevention (CDC) put patients with T2DM at higher risk for severe COVID-19 outcomes than T1DM, major medical societies urged that both groups should be prioritized equally. Others have argued that younger patients with DM should be prioritized early for vaccine rollout because they "disproportionately impacted in terms of life years lost and are of working age, which puts them at potentially higher risk of exposure, alongside the excess relative COVID-19 mortality risk in younger people with diabetes". [104] CDC has since then, prioritized T1DM and T2DM equally for vaccination. Thus, in light of the available evidence, COVID-19 vaccination should be prioritized early for DM patients, irrespective of age or type of diabetes.

The implementation of lockdown and travel restrictions requires attention since the delivery of generalized and specialized medical services is limited. [105] Patients with chronic noncommunicable diseases, such as DM and its associated complications, are at risk, since their routine medical follow-up schedule is affected due to the restrictions. These patients are at risk of both adverse outcomes and more severe COVID-19 since physical inactivity might seem to be related to their well-being and without access to routine medical care. [4, [106] [107] [108] [109] [110] Previous SARS-CoV outbreak has shown a possibility of long-lasting metabolic alteration, which may predispose patients to cardiovascular diseases. [111] Therefore, the surge of non-communicable diseases has to be anticipated by implementing new strategies to advance health-related technologies and telemedicine. [109] Conclusions Diabetes is a prevalent chronic disease that is independently associated with poor outcomes in COVID-19 patients. Thus, appropriate interventions are needed to mitigate the increased risk faced by this population. With vaccines available, vaccinating this population is the crucial first J o u r n a l P r e -p r o o f 

Global and regional diabetes prevalence estimates for

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -A systematic review, meta-analysis, and meta-regression: Diabetes and COVID-19

Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy

Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area

Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection

The effect of short-term hyperglycemia on the innate immune system

Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement

COVID-19 pandemic, coronaviruses, and diabetes mellitus

Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Structural biology: Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

COVID-19 and diabetes mellitus: from pathophysiology to clinical management

Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis

Relationship between natural killer cell activity and glucose control in patients with type 2 diabetes and prediabetes

Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning

Diabetes epidemiology in the covid-19 pandemic

Prevalence of diabetes and hypertension and their associated risks for poor outcomes in Covid-19 Patients

Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study

Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a populationbased cohort study

Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland

Type 2 diabetes and covid-19-related mortality in the critical care setting: A national cohort study in england

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results CORONADO study

Type 1 diabetes in people hospitalized for covid-19: New insights from the coronado study

COVID-19 Hospitalization in Adults with Type 1 Diabetes: Results from the T1D Exchange Multicenter Surveillance Study

Clinical Characteristics of Covid-19 in New York City

Body mass index and outcome in patients with COVID-19: A dose-response meta-analysis

Association of obesity and its genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort data

COVID-19 in people with diabetes: understanding the reasons for worse outcomes

Mechanism linking diabetes mellitus and obesity

Obesity and impaired metabolic health in patients with COVID-19

Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease

Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms

Circulating mononuclear cells in the obese are in a proinflammatory state

Does Coronavirus Disease 2019 Disprove the Obesity Paradox in Acute Respiratory Distress Syndrome?

Relationship between obesity and severe COVID-19 outcomes in patients with type 2 diabetes: Results from the CORONADO study

Obesity and SARS-CoV-2: A population to safeguard

Visceral fat shows the strongest association with the need of intensive care in patients with COVID-19

Visceral Adiposity, Subcutaneous Adiposity, and Severe Coronavirus Disease-2019 (COVID-19): Systematic Review and Meta-Analysis

Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico

A pragmatic approach to inpatient diabetes management during the COVID-19 pandemic

Management of diabetes and hyperglycemia in the hospital: A practical guide to subcutaneous insulin use in the noncritically ill, adult patient

Practical recommendations for the management of diabetes in patients with COVID-19

How diabetes management is adapting amid the COVID-19 pandemic

COVID-19, type 1 diabetes, and technology: why paediatric patients are leading the way

Usefulness and Safety of Remote Continuous Glucose Monitoring for a Severe COVID-19 Patient with Diabetes

The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth

Managing New-Onset Type 1 Diabetes During the COVID-19 Pandemic: Challenges and Opportunities

Diabetes Telehealth Solutions: Improving Self-Management Through Remote Initiation of Continuous Glucose Monitoring

Continuous Glucose Monitoring in the Intensive Care Unit During the COVID-19 Pandemic

Remote Glucose Monitoring Platform for Multiple Simultaneous Patients at Coronavirus Disease 2019 Intensive Care Units: Case Report Including Adults and Children

Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States

Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: A retrospective cohort study

Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

Admission fasting blood glucose predicts 30-day poor outcome in patients hospitalized for COVID-19 pneumonia

J-shaped association between fasting blood glucose levels and COVID-19 severity in patients without diabetes

Outcomes in Patients with Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic

Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: The pisa COVID-19 study

High admission blood glucose independently predicts poor prognosis in COVID-19 patients: A systematic review and dose-response meta-analysis

Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications

Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status

The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis

Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors

The biology of incretin hormones

Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV

Regulation of chemokine activity -A focus on the role of dipeptidyl peptidase IV/CD26

Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance

Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study

Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: A disproportionality analysis in the World Health Organization VigiBase

Use of oral antidiabetic agents and risk of community-acquired pneumonia: a nested case-control study

The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study

No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19

Sitagliptin treatment J o u r n a l P r e -p r o o f Journal Pre-proof at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and covid-19: A multicenter case-control retrospective observational study

Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) -A systematic review, meta-analysis, and meta-regression

Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4

Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes

Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes

Acute kidney injury from SGLT2 J o u r n a l P r e -p r o o f Journal Pre-proof inhibitors: Potential mechanisms

The mode of action of thiazolidinediones

Peroxisome proliferatoractivated receptor γ ligands inhibit development of atherosclerosis in LDL receptordeficient mice

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 Diabetes

Impact of comorbidities and glycemia at admission and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes with covid-19: A case series from an academic hospital in lombardy, italy

Pancreatic Injury Patterns in Patients With Coronavirus Disease 19 Pneumonia

New-Onset Diabetes in Covid-19

Characteristics of and Mortality Associated With Diabetic Ketoacidosis Among US Patients Hospitalized With or Without COVID-19

Managing hyperglycemia in the covid-19 inflammatory storm

Hyperglycemia: An independent marker of in-hospital mortality in patients with undiagnosed diabetes

Commentary: COVID-19 in patients with diabetes

Stress hyperglycaemia

COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges

Robust neutralizing antibodies to SARS-CoV-2 develop and persist in subjects with diabetes and COVID-19 pneumonia

Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study

The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation

A wave of non-communicable diseases following the COVID-19 pandemic

Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression

Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases

COVID-19 pandemic and challenges for socio-economic issues, healthcare and National Health Programs in India

Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19

Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, metaanalysis, and meta-regression

Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection

Authors Contribution

Conceptualization, Design, Investigation, Writing -Original Draft, Writing -Review and Editing Joshua Henrina: Conceptualization, Design, Investigation, Writing -Original Draft

Conceptualization, Design, Investigation, Writing -Original Draft Sherly Lawrensia: Investigation, Writing -Original Draft Ian Huang: Investigation, Writing -Review and Editing J o u r n a l P r e